Which biological response modifiers are heading for success? Gill Higgins Newsletter Article 04 February 2013 Pages: 3 - 4
Bacteriuria screening and treatment ‘cost beneficial’ during pregnancy Newsletter Article 04 February 2013 Pages: 6 - 6
Don’t waste healthcare resources on treating acute bronchiolitis Newsletter Article 04 February 2013 Pages: 7 - 7
ZD-1694 produces encouraging results in phase III cancer trial Newsletter Article 04 February 2013 Pages: 8 - 8
Edatrexate not recommended for squamous cell carcinoma Newsletter Article 04 February 2013 Pages: 10 - 10
Tauroursodeoxycholic acid useful in chronic hepatitis Newsletter Article 04 February 2013 Pages: 11 - 11
Meropenem: an effective alternative for complicated UTIs Newsletter Article 04 February 2013 Pages: 12 - 12
Rapid metabolic control of diabetes reduces mortality after MI Newsletter Article 04 February 2013 Pages: 12 - 12
Saquinavir offers promising options for delaying resistance in HIV infection Sean Henahan Newsletter Article 04 February 2013 Pages: 13 - 14
Epoetin-α helps anaemia of HIV infection and renal failure Newsletter Article 04 February 2013 Pages: 14 - 14
Ramipril + piretanide better than monotherapy for hypertension Newsletter Article 04 February 2013 Pages: 14 - 14
Intradural urokinase is effective for dural sinus thrombosis Newsletter Article 04 February 2013 Pages: 15 - 15
Evening sustained-release isradipine more effective in renal failure Newsletter Article 04 February 2013 Pages: 17 - 17
Lanreotide in restenosis prevention after angioplasty Newsletter Article 04 February 2013 Pages: 18 - 18
Picibanil enhances cell regeneration after hepatectomy Newsletter Article 04 February 2013 Pages: 19 - 19
Avoid GM-CSF in limited-stage small-cell lung cancer Newsletter Article 04 February 2013 Pages: 21 - 21
Pancreatic enzymes lose nonprescription status in the US Newsletter Article 04 February 2013 Pages: 21 - 21